fbpx

EMMA test

EMMA (Endometrial Microbiome Metagenomic Analysis) 

Metagenomic analysis of the endometrial microbiome is a screening test for microbiological evaluation of the endometrium.

The EMMA test identifies the ten most common bacteria in the endometrium by determining the percentage of lactobacilli and dysbiotic bacteria present, thus improving the clinical treatment of infertility in women.

Scientific surveys have found that pathological changes in the endometrial microflora are associated with poor reproductive outcomes for patients treated with assisted reproduction methods.

Benefits

The EMMA test determines the percentage of lactobacilli present in the endometrium to improve the patient’s reproductive prognosis. EMMA also indicates the possible presence of bacterial pathogens that can cause chronic endometritis or other diseases. If the endometrium is not dominated by lactobacilli, the test result will suggest appropriate treatment for the patient. The EMMA will determine if the microbial environment of the uterus is optimal for embryo implantation.

Indications

The influence of the endometrial microbiome has been established in patients with recurrent implantation failures. By assessing the microbiological environment that the embryo will encounter during implantation, the EMMA test can be beneficial for any patient who wishes to conceive.

Technology

EMMA uses the latest Next Generation Sequencing (NGS) technology to provide microbiometric information about endometrial tissue by analyzing the full profile of the endometrial microbiome.

Molecular evaluation of the microbiome, using NGS, allows the detection of cultured and uncultivated bacteria.

Prices

Metagenomic analysis of the endometrial microbiome / EMMA /

1190 BGN